iRay Group

iRay Group ROE

The Return on Equity (ROE) of iRay Group (688301.SS) as of Oct 18, 2026 is 10.89 %. In the previous year, Return on Equity (ROE) was 10.03 % — a change of 8.62% (higher).

ROE

10.89 %

YoY

8.62%

Last updated:

In 2025, iRay Group's return on equity (ROE) was 10.89 %, a 8.62% increase from the 10.03 % ROE in the previous year.

The iRay Group ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
18.38 CNY
Jan 1, 2019
22.65 CNY
Jan 1, 2020
8.44 CNY
Jan 1, 2021
15.86 CNY
Jan 1, 2022
16.54 CNY
Jan 1, 2023
14.03 CNY
Jan 1, 2024
10.03 CNY
Jan 1, 2025
10.89 CNY
The iRay Group ROE history
YEARROEYoY
10.89 %+8.62%
10.03 %-28.52%
14.03 %-15.20%
16.54 %+4.31%
15.86 %+87.92%
8.44 %-62.75%
22.65 %+23.23%
18.38 %-14.99%
21.62 %-10.16%
24.07 %+71.52%
14.03 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

iRay Group Stock analysis

What does iRay Group do? iRay Group, operating under the ticker symbol 688301.SS and identified by ISIN CNE1000042V8, is a prominent entity within the Chinese healthcare sector. Headquartered in Shanghai, the company has established itself as a significant player in the medical technology industry, specifically focusing on the development and manufacturing of advanced digital imaging solutions. The organization went public on September 18, 2020, marking a pivotal moment in its corporate history and allowing it to expand its operational capabilities on a broader scale. As of the latest available data, iRay Group employs a workforce of 1,237 full-time employees, reflecting its substantial operational footprint and commitment to human capital in driving technological innovation. The core business of the company revolves around the research, development, production, and sale of digital X-ray detectors, which are critical components in modern medical diagnostic equipment. These detectors are engineered to provide high-resolution imaging, enabling healthcare professionals to make accurate and timely diagnoses. The product portfolio of iRay Group is diverse and tailored to meet various clinical and industrial needs. Key product lines include the universal radio frequency series, which offers versatile imaging solutions for general diagnostic purposes. Additionally, the company manufactures specialized breast series detectors designed specifically for mammography, ensuring high sensitivity and image clarity for early detection of breast abnormalities. The radiotherapy series further expands the company's reach into therapeutic applications, providing essential imaging support for radiation treatment planning and monitoring. Beyond the medical sector, the technology developed by iRay Group finds application in industrial non-destructive testing and security inspection fields. This diversification highlights the robustness of their detector technology, which can be adapted for inspecting materials integrity in manufacturing or screening for security threats. The company maintains a comprehensive distribution network that serves both the domestic market within China and international markets overseas. This global reach underscores the competitive quality of their products and the company's strategic focus on expanding its presence in the worldwide healthcare and industrial technology sectors. By leveraging its expertise in digital X-ray technology, iRay Group continues to contribute to advancements in medical diagnostics and industrial safety, positioning itself as a key innovator in the health care industry. iRay Group is one of the most popular companies on Eulerpool.

ROE Details

Decoding iRay Group's Return on Equity (ROE)

iRay Group's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing iRay Group's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

iRay Group's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in iRay Group’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about iRay Group stock

Return on Equity (ROE) of iRay Group is 10.89 % in 2025.

Return on Equity (ROE) of iRay Group changed from 10.03 % to 10.89 %, representing a 8.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) iRay Group since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s iRay Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — iRay Group

All Key Metrics — iRay Group